Answers are grounded in this paper and cite their sources.
Introduction Pancreatoduodenectomy remains the standard of care for ampullary carcinoma, however the role of adjuvant chemotherapy remains unclear. We investigated the survival benefits of single vs. multi-agent chemotherapy regimens. Methods The National Cancer Database (NCDB) was queried to identify patients ≥18 years old diagnosed with stage II or III carcinoma of the ampulla of Vater between years 2013-2020. Multi-agent usage increased dramatically in 2017, so we categorized by years 2013-2016 vs. 2017-2020. Propensity score matching was performed separately for stage II and III disease using age, race, number of comorbidities and year. Kaplan-Meier (K-M) analysis compared overall survival by single vs. multi-agent chemotherapy for 2013-2016 and 2017-2020. Cox regression analysis examined differences by number of agents while controlling for age, race, number of comorbidities, and year. Results 1207 patients were included in the propensity-matched cohort: 477 who received single vs. 730 who received multi-agent chemotherapy. K-M analyses demonstrated that for 2013-2016, multi-agent therapy showed a significantly longer average survival for both stage II (55.99 vs. 51.43 months) and III (55.90 vs. 50.78 months) disease (p<0.01). Follow up for the 2017 – 2020 cohort was inadequate for accurate survival reporting. Upon multivariate analysis, a significant advantage in survival with multi-agent chemotherapy was maintained for stage II (HR: 1.44, 95% CI: 1.14-1.82, p<0.01) and stage III (HR: 1.41, 95% CI: 1.09-1.83 , p=0.01) disease. Conclusion For resected, locally advanced ampullary cancer, multi-agent chemotherapy was found to have a significant improvement in overall survival compared to single agent chemotherapy for stage II and III disease.
No takes yet. Share an insight, caveat, or question.
Warshowsky et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: